Atara Biotherapeutics, Inc.
ATRA
$9.81
$1.0311.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.33% | 51.27% | 202.41% | 475.53% | 1,404.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.33% | 51.27% | 202.41% | 475.53% | 1,404.02% |
| Cost of Revenue | -64.12% | -55.80% | -26.85% | -43.88% | -46.37% |
| Gross Profit | 1,058.11% | 284.82% | 180.68% | 146.84% | 103.02% |
| SG&A Expenses | -39.55% | -25.63% | -13.31% | -15.18% | -22.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -63.14% | -47.99% | -26.28% | -20.57% | -25.40% |
| Operating Income | 156.65% | 131.48% | 111.58% | 98.54% | 70.91% |
| Income Before Tax | 138.31% | 117.58% | 103.18% | 93.27% | 69.06% |
| Income Tax Expenses | 358.33% | -33.33% | -306.25% | -311.76% | -180.00% |
| Earnings from Continuing Operations | 138.28% | 117.57% | 103.20% | 93.29% | 69.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 138.28% | 117.57% | 103.20% | 93.29% | 69.07% |
| EBIT | 156.65% | 131.48% | 111.58% | 98.54% | 70.91% |
| EBITDA | 166.14% | 136.53% | 115.30% | 101.04% | 72.29% |
| EPS Basic | 124.56% | 108.67% | 99.00% | 93.03% | 80.29% |
| Normalized Basic EPS | 133.36% | 114.06% | 101.75% | 94.61% | 81.22% |
| EPS Diluted | 124.24% | 108.51% | 98.90% | 92.97% | 80.28% |
| Normalized Diluted EPS | 133.04% | 113.90% | 101.64% | 94.54% | 81.22% |
| Average Basic Shares Outstanding | 67.48% | 100.51% | 102.17% | 90.58% | 76.71% |
| Average Diluted Shares Outstanding | 68.15% | 101.36% | 103.16% | 91.05% | 76.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |